Faldaprevir is an investigational antiviral agent developed for the treatment of chronic hepatitis C virus (HCV) infection, specifically targeting genotype 1. It functions as a potent inhibitor of the HCV NS3/4A protease, an enzyme essential for viral replication. By blocking this enzyme, faldaprevir prevents the virus from maturing and producing infectious particles, thereby reducing viral load in patients. It was studied in combination with other antiviral agents, such as pegylated interferon and ribavirin, in clinical trials to improve sustained virologic response rates. Faldaprevir showed promise in both treatment-naïve patients and those who had previously failed standard therapy. Its development aimed to shorten treatment duration and improve outcomes in HCV therapy. Although clinical development was discontinued due to strategic portfolio decisions by the manufacturer, data from faldaprevir trials contributed to the understanding of protease inhibitor-based regimens in HCV treatment.